Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-5-22
pubmed:abstractText
Inherited hemophilia dog and other transient hemophilic animal models have been used for evaluation of hemostatic agents for use in treatment of hemophilia. We established the first nonhuman primate hemophilic model by immunizing cynomolgus monkeys with human FIX (hFIX) in adjuvants. FIX activities of all three hFIX-immunized monkeys decreased transiently to less than 10% in accordance with prolongation of activated partial thromboplastin time (APTT). Forty micrograms of human factor VIIa (hFVIIa) per kilogram body weight (that was reported to be clinically effective) was administered to the monkey with the highest inhibitor titer to evaluate its usefulness as a hemophilia inhibitor model. Results of thromboelastography (TEG) after the injection demonstrated that the hemostatic effect of FVIIa in this model would be similar to that in hemophiliacs with inhibitors. The antibodies purified from the monkey's plasma by hFIX-immobilized gel were composed of two types: Ca(2+)-dependent and -independent antibodies, with features of IgG(1) and IgG(4). Both types of antibodies reacted to cynomolgus FIX, and only Ca(2+)-dependent antibodies also expressed inhibitory activity against cynomolgus FIX. Immunoblotting analyses of Ca(2+)-dependent antibodies using hFIX and its derivatives suggested that they recognized the Ca(2+)-dependent conformation related to the gamma-carboxyglutamic acid (Gla) domain. Comparison of FIX cDNA from human, cynomolgus monkey, and other species, and the results of immunization of various animals (goats, beagle dogs, rabbits, and rats) with hFIX in adjuvants strongly suggested that the development of acquired FIX inhibitors in the monkeys might be due to high cross-reactivity of the antibodies to molecular mimic antigens, hFIX, and cynomolgus FIX.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0049-3848
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
102
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
363-74
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:11369429-Animals, pubmed-meshheading:11369429-Antibodies, Heterophile, pubmed-meshheading:11369429-DNA Primers, pubmed-meshheading:11369429-Disease Models, Animal, pubmed-meshheading:11369429-Dogs, pubmed-meshheading:11369429-Factor IX, pubmed-meshheading:11369429-Factor VIIa, pubmed-meshheading:11369429-Goats, pubmed-meshheading:11369429-Hemophilia B, pubmed-meshheading:11369429-Hemostasis, pubmed-meshheading:11369429-Humans, pubmed-meshheading:11369429-Immunization, pubmed-meshheading:11369429-Immunoglobulin G, pubmed-meshheading:11369429-Liver, pubmed-meshheading:11369429-Macaca fascicularis, pubmed-meshheading:11369429-Partial Thromboplastin Time, pubmed-meshheading:11369429-Platelet Count, pubmed-meshheading:11369429-Polymerase Chain Reaction, pubmed-meshheading:11369429-Prothrombin Time, pubmed-meshheading:11369429-Rabbits, pubmed-meshheading:11369429-Rats, pubmed-meshheading:11369429-Rats, Wistar, pubmed-meshheading:11369429-Time Factors
pubmed:year
2001
pubmed:articleTitle
Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
pubmed:affiliation
Kaketsuken (The Chemo-Sero-Therapeutic Research Institute), Kumamoto, Japan. tomokiyo@kaketsuken.or.jp
pubmed:publicationType
Journal Article